Factors influencing the emergence of resistance to indinavir: Role of virologic, immunologic, and pharmacologic variables

56Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A major problem with the use of human immunodeficiency virus type 1 (HIV-1) protease inhibitors as monotherapy has been an unacceptably high rate of emergence of resistance. To examine possible influences on the time to emergence of resistance, 24-week data were examined from five studies in which indinavir had been administered as monotherapy or as a component of combination therapy. Monotherapy data indicated a correlation between the level of HIV-1 RNA achieved and the risk of emergence of resistance: the lower the level, the lower the risk. When combination and monotherapy regimens were compared, the group receiving indinavir + lamivudine + zidovudine had a significantly lower risk of resistance, even after adjusting for the minimum HIV-1 RNA level achieved. The findings indicate that if at all possible, HIV-1-infected patients should receive combination chemotherapy to minimize the emergence of resistance to the protease inhibitor portion of the regimen. The goal of therapy should be to decrease the HIV-1 RNA load to a less-than-detectable level.

Cite

CITATION STYLE

APA

Drusano, G. L., Bilello, J. A., Stein, D. S., Nessly, M., Meibohm, A., Emini, E. A., … Holder, D. J. (1998). Factors influencing the emergence of resistance to indinavir: Role of virologic, immunologic, and pharmacologic variables. Journal of Infectious Diseases, 178(2), 360–367. https://doi.org/10.1086/515631

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free